Compare Cronos Group Inc (CRON) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Schwab US Large Cap Growth ETF — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Schwab US Large Cap Growth ETF trades at $34.64. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | SCHG | |
|---|---|---|
Market Cap | $1.02B | — |
Sector | Health | Sector/Thematic |
52-Week High | $3.27 | $35.30 |
52-Week Low | $1.95 | $28.10 |
Enterprise Value | $203.29M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.37, down 0.81% on the day. The technical outlook is bullish with moving averages signaling strength, while oscillators are neutral. Recent news highlights its concentrated exposure to AI-driven tech giants like Nvidia, Apple, and Microsoft, positioning it for potential growth from AI capital expenditure trends. The fund's portfolio carries a P/E around 32x, reflecting premium valuations amid moderate 2026 performance.
Outlook: SCHG offers leveraged growth potential through top tech holdings but faces risks from high concentration and interest rate sensitivity. Upside hinges on AI adoption, while downside could stem from tech sector volatility or economic shifts. Institutional inflows suggest confidence, yet investors must weigh valuation against diversification limits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
